We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Regulatory Efforts to Facilitate Evaluation and Clinical Management of Drug‐Drug Interaction Risks.
- Authors
Yang, Xinning; Pfuma Fletcher, Elimika; Huang, Shiew‐Mei; Zineh, Issam; Madabushi, Rajanikanth
- Abstract
Regulatory Efforts to Facilitate Evaluation and Clinical Management of Drug-Drug Interaction Risks The FDA-DDI List classifies those drugs into strong, moderate, or weak inhibitors or inducers, and sensitive or moderately sensitive substrates of various CYP enzymes. In the analysis conducted by Cicali I et al i ., the fold-change in substrate AUC was calculated for each inhibitor as the ratio of the arithmetic mean AUC of substrate plus inhibitor over substrate alone. Clinical drug-drug interaction evaluations to inform drug use and enable drug access.
- Subjects
ABIRATERONE acetate; MEDICAL personnel; CASTRATION-resistant prostate cancer
- Publication
Clinical Pharmacology & Therapeutics, 2021, Vol 109, Issue 1, p42
- ISSN
0009-9236
- Publication type
Article
- DOI
10.1002/cpt.1984